Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Rocket Companies Inc. Class A Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.15 (market cap $6.57B), while Rocket Companies Inc. Class A Common Stock trades at $10.55 (market cap $30.67B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 4.7× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| IOVA | RKT | |
|---|---|---|
Market Cap | $6.57B | $30.67B |
Volume | 11,838,721 | 41,104,143 |
Sector | Health | Financials |
52-Week High | $14.82 | $23.44 |
52-Week Low | $1.81 | $10.53 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $60.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
